Amplification of the anonymous marker D17S67 in malignant astrocytomas

1994 ◽  
Vol 9 (2) ◽  
pp. 148-152 ◽  
Author(s):  
Emilia K. Bijlsma ◽  
Andries Westerveld ◽  
Theo J. M. Hulsebos ◽  
Sieger Leenstra ◽  
D. Andries Bosch
Keyword(s):  
Malignant Astrocytomas ◽  
Anonymous Marker

scholarly journals Critical Appraisal of Experimental Radiation Modalities for Malignant Astrocytomas

1990 ◽  
Vol 17 (2) ◽  
pp. 199-208 ◽  
Author(s):  
N.J. Laperriere
Keyword(s):  
Critical Appraisal ◽  
Clinical Results ◽  
Particle Therapy ◽  
Postoperative Radiation ◽  
Postoperative Radiation Therapy ◽  
Initial Management ◽  
Altered Fractionation ◽  
Malignant Astrocytomas ◽  
Prospective Trials ◽  
Radiation Sensitizers

ABSTRACT:The management of patients with supratentorial malignant astrocytomas has remained a major problem. Patients continue to die from a lack of local control in 90% of cases despite an improvement of median survival seen with the use of postoperative radiation therapy. Because of this, there has been considerable interest in exploring novel ways of possibly improving results. This paper reviews the rationale and clinical results with the use of altered fractionation schemes, brachytherapy, radiation sensitizers, hyperthermia, particle therapy, and radiosurgery in the treatment of these patients. Currently, there is no demonstrated advantage with the use of these experimental modalities in the initial management of patients. There would appear to be some benefit for selected patients who are treated with brachytherapy at recurrence, but its efficacy as part of initial management remains to be determined in ongoing randomized prospective trials.

scholarly journals EPID-18. TRENDS IN INCIDENCE AND SURVIVAL OF MALIGNANT PEDIATRIC CENTRAL NERVOUS SYSTEM TUMORS IN THE NETHERLANDS

2020 ◽  
Vol 22 (Supplement_3) ◽  
pp. iii322-iii322
Author(s):  
Raoull Hoogendijk ◽  
Jasper van der Lugt ◽  
Dannis van Vuurden ◽  
Eelco Hoving ◽  
Leontien Kremer ◽  
...  
Keyword(s):  
Central Nervous System ◽  
Nervous System ◽  
The Netherlands ◽  
Malignant Gliomas ◽  
Survival Rates ◽  
Tumor Patients ◽  
Netherlands Cancer Registry ◽  
Malignant Astrocytomas ◽  
Brainstem Tumors ◽  
The Impact

Abstract BACKGROUND Variation in survival of pediatric central nervous system (CNS) tumors is large between countries. Within Europe, the Netherlands had one of the worst reported survival rates of malignant CNS (mCNS) tumors during 2000–2007. METHODS Using the Netherlands Cancer Registry, we evaluated trends in incidence and survival of pediatric mCNS tumors (behavior /3, 5th digit in the morphology code) diagnosed between 1990–2017. RESULTS 839 newly-diagnosed mCNS tumor patients <18 years were registered between 1990–2017. Incidence of mCNS tumors remained stable (average incidence rate, 21.6 per million person-years). However, an increased incidence of malignant gliomas, NOS was found (Estimated Annual Percentage Change (EAPC) 11.6% p<0.001). This appears to be related to a registration shift between 1990–1999 and 2000–2009 as brainstem tumors increased (+25%, n=79) for astrocytomas and other gliomas but decreased (-31%, n=32) for unspecified intracranial and intraspinal neoplasms. Overall, 5-year observed survival (5Y-OS) of mCNS tumors increased from 51% in 1990–1999 to 61% in 2010–2017 (P-for-trend<0.001). This increase was not constant over time, as 5Y-OS for the period 2000–2009 was 47%. The only significant decrease in survival was found for malignant astrocytomas and other gliomas with a 5Y-OS of 56% in 1990–1999 decreasing to 48% in 2010–2017 (P-for-trend<0.001). CONCLUSION Between 1990–2017 incidence of mCNS tumors in the Netherlands remained stable and survival increased. However, a decrease in survival was seen for malignant astrocytomas and other gliomas, which is partially explained by the registration shift of brainstem tumors. The impact of this shift on survival for all mCNS tumors is subject to further research.

Human interferon beta, nimustine hydrochloride, and radiation therapy in the treatment of newly diagnosed malignant astrocytomas

2005 ◽  
Vol 72 (1) ◽  
pp. 57-62 ◽  
Author(s):  
Takao Watanabe ◽  
Yoichi Katayama ◽  
Atsuo Yoshino ◽  
Chikashi Fukaya ◽  
Takamitsu Yamamoto
Keyword(s):  
Radiation Therapy ◽  
Interferon Beta ◽  
Human Interferon ◽  
Newly Diagnosed ◽  
Malignant Astrocytomas ◽  
Nimustine Hydrochloride

Cordotomy for patients with thoracic malignant astrocytoma

2010 ◽  
Vol 13 (4) ◽  
pp. 418-423 ◽  
Author(s):  
Masaya Nakamura ◽  
Osahiko Tsuji ◽  
Kanehiro Fujiyoshi ◽  
Kota Watanabe ◽  
Takashi Tsuji ◽  
...  
Keyword(s):  
Tumor Resection ◽  
Radical Resection ◽  
Subtotal Resection ◽  
Optimal Management ◽  
Malignant Astrocytoma ◽  
Initial Operation ◽  
Who Grade ◽  
Kaplan Meier ◽  
Malignant Astrocytomas ◽  
Grade Ii

Object The optimal management of malignant astrocytomas remains controversial, and the prognosis of these lesions has been dismal regardless of the administered treatment. In this study the authors investigated the surgical outcomes of cordotomy in patients with thoracic malignant astrocytomas to determine the effectiveness of this procedure. Methods Cordotomy was performed in 5 patients with glioblastoma multiforme (GBM) and 2 with anaplastic astrocytoma (AA). A Kaplan-Meier survival analysis was performed, and the associations of the resection level with survival and postoperative complications were retrospectively examined. Results Cordotomy was performed in a single stage in 2 patients with GBM and in 2 stages in 3 patients with GBM and 2 patients with AA. In the 2 patients with GBM, cordotomy was performed 2 and 3 weeks after a partial tumor resection. In the 2 patients with AA, the initial treatment consisted of partial tumor resection and subtotal resection combined with radiotherapy, and rostral tumor growth and progressive paralysis necessitated cordotomy 2 and 28 months later. One patient with a secondary GBM underwent cordotomy; the GBM developed 1 year after subtotal resection and radiotherapy for a WHO Grade II astrocytoma. Four patients died 4, 5, 24, and 42 months after the initial operation due to CSF dissemination, and 3 patients (2 with GBM and 1 with AA) remain alive (16, 39, and 71 months). No metastasis to any other organs was noted. Conclusions One-stage cordotomy should be indicated for patients with thoracic GBM or AA presenting with complete paraplegia preoperatively. In patients with thoracic GBM, even if paralysis is incomplete, cordotomy should be performed before the tumor disseminates through the CSF. Radical resection should be attempted in patients with AA and incomplete paralysis. If the tumor persists, radiotherapy and chemotherapy are indicated, and cordotomy should be reserved for lesions growing progressively after such second-line treatments.

scholarly journals Prognostic Factors and Survival in Primary Malignant Astrocytomas of the Spinal Cord

Spine ◽  
2012 ◽  
Vol 37 (12) ◽  
pp. E727-E735 ◽  
Author(s):  
Hadie Adams ◽  
Javier Avendaño ◽  
Shaan M. Raza ◽  
Ziya L. Gokaslan ◽  
George I. Jallo ◽  
...  
Keyword(s):  
Spinal Cord ◽  
Prognostic Factors ◽  
Malignant Astrocytomas

Fast neutrons and misonidazole for malignant astrocytomas

1985 ◽  
Vol 11 (4) ◽  
pp. 679-686 ◽  
Author(s):  
Parvathy D. Kurup ◽  
Thomas F. Pajak ◽  
Frank R. Hendrickson ◽  
James S. Nelson ◽  
Joanne Mansell ◽  
...  
Keyword(s):  
Fast Neutrons ◽  
Malignant Astrocytomas

Quality of life and neuropsychological evaluation for patients with malignant astrocytomas: RTOG 91-14

1997 ◽  
Vol 38 (1) ◽  
pp. 9-20 ◽  
Author(s):  
Ali K. Choucair ◽  
Charles Scott ◽  
Raul Urtasun ◽  
Diana Nelson ◽  
Benjamin Mousas ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Neuropsychological Evaluation ◽  
Malignant Astrocytomas

Brain Tumors during the First Twenty-four Months of Life

Neurosurgery ◽  
1985 ◽  
Vol 17 (6) ◽  
pp. 913-919 ◽  
Author(s):  
Tadanori Tomita ◽  
David G. McLone
Keyword(s):  
Mortality Rate ◽  
Brain Tumors ◽  
Choroid Plexus Papilloma ◽  
Signs And Symptoms ◽  
Tumor Location ◽  
Surgical Mortality ◽  
Malignant Astrocytomas ◽  
Suprasellar Region ◽  
4Th Ventricle ◽  
Common Histological Type

Abstract One hundred patients with brain tumors were diagnosed and treated during the first 24 months of life. They represent 16% of 608 children with brain tumors treated from 1952 through 1984. The most common histological type of brain tumors during the first 24 months are benign astrocytoma, medulloblastoma, and choroid plexus papilloma. The tumor location is distributed relatively evenly among the cerebellum and the 4th ventricle, the cerebral hemisphere (including the lateral ventricle), and the suprasellar region and 3rd ventricle. The chief presenting signs and symptoms are a full fontanelle, macrocephaly, changes of behavior, and delayed developmental milestones. Localizing signs are infrequent. Ninety-two patients underwent craniotomy with a one-month surgical mortality rate of 12%. The surgical mortality rate was 5.6% among 36 recent patients diagnosed by computed tomography. The 5-year survival rate is 41% in the patients younger than 12 months and 74% in patients diagnosed during the 2nd year of life. This study indicates the validity of Collins' rule for medulloblastomas during the first 24 months of life, but not for benign or malignant astrocytomas.

Sign in / Sign up

Export Citation Format

Share Document